For most people at high risk of osteoporotic fractures and no history of heart attack or stroke, Evenity offers the strongest and fastest bone-building effect of any available osteoporosis drug. It cut the risk of new spinal fractures in half compared to alendronate (a standard treatment) over two years, and it builds more bone density than any competitor in its 12-month treatment window. But it carries a boxed warning about cardiovascular events, which makes the risk-benefit calculation genuinely personal. Here’s what the evidence actually shows so you can have a more informed conversation with your doctor.
What Evenity Does Differently
Most osteoporosis drugs work in one direction: they either slow bone breakdown or stimulate new bone growth. Evenity does both at the same time. It blocks a protein called sclerostin, which your bone cells naturally produce to put the brakes on bone formation. When that protein is neutralized, two things happen simultaneously. Your body ramps up the production of new bone, and it slows the process that dissolves old bone. This dual action is why Evenity builds bone density faster than other treatments.
In a head-to-head comparison with teriparatide (the other major bone-building drug), Evenity produced significantly greater gains in bone density at every measured site after 12 months. At the total hip, the difference was 5.4 percentage points in Evenity’s favor. At the femoral neck and lumbar spine, the gaps were 4.7 and 4.5 percentage points, respectively. For someone whose bones are fragile enough to fracture, that margin matters.
How Much It Reduces Fracture Risk
The landmark ARCH trial compared Evenity followed by alendronate against alendronate alone. At 24 months, patients who started on Evenity had a 50% lower risk of new vertebral fractures, a 27% lower risk of clinical fractures (fractures that cause symptoms), and a 19% lower risk of non-vertebral fractures. Those numbers are relative reductions, meaning the benefit is largest for people whose baseline fracture risk is already high. If your risk of a spinal fracture in the next few years is substantial, cutting it in half is a meaningful change.
These results are particularly notable because the comparison group wasn’t taking a placebo. They were on alendronate, which is itself an effective osteoporosis treatment. Evenity outperformed an already-proven drug by a wide margin, which is unusual in osteoporosis trials.
The Cardiovascular Concern
Evenity carries an FDA boxed warning, the most serious type. During the ARCH trial, more cardiovascular events (heart attacks, strokes, and cardiovascular deaths) occurred in the Evenity group than in the alendronate group during the first 12 months. This difference is what prompted regulators to act.
The drug is contraindicated if you’ve had a heart attack or stroke at any point in your life. That’s a hard line, not a judgment call. Beyond that absolute rule, the warning advises weighing cardiovascular risk factors before starting treatment. If you have uncontrolled high blood pressure, diabetes, high cholesterol, a history of smoking, or kidney disease, the calculus shifts. None of those are automatic disqualifiers, but each one adds weight to the risk side of the equation.
It’s worth noting that the cardiovascular signal appeared specifically in the comparison against alendronate, which itself may have mild cardioprotective properties. Some researchers have questioned whether the difference reflects Evenity increasing risk, alendronate decreasing risk, or some combination. That ambiguity hasn’t been fully resolved, which is part of why the question “is it worth it” doesn’t have a universal answer.
Common Side Effects Beyond the Heart
Setting aside the cardiovascular warning, Evenity’s everyday side effect profile is relatively manageable. Joint pain is the most common complaint, affecting about 13% of patients in clinical trials. Headaches and tingling or numbness (paresthesia) each occur in 1% to 10% of people. These side effects are generally mild and don’t lead most patients to stop treatment.
Evenity is given as two injections under the skin, once a month, administered by a healthcare professional. You can’t take it at home. Some people experience redness or soreness at the injection site, but this typically fades quickly.
Who Is a Strong Candidate
The FDA approved Evenity specifically for postmenopausal women at high risk for fracture. That means women who have already broken a bone due to osteoporosis, who have multiple risk factors for fracture, or who have tried other osteoporosis medications that didn’t work or caused intolerable side effects. It’s not a first-line drug for someone with mildly low bone density and no fracture history.
The people who benefit most tend to fall into a specific profile: severe osteoporosis, especially with previous fractures, and no cardiovascular history. If you’ve already fractured a hip or spine and your bone density is very low, the risk of another fracture (which itself carries serious health consequences, including increased mortality in older adults) may well outweigh the cardiovascular uncertainty. A spinal or hip fracture in a 70- or 80-year-old can trigger a cascade of immobility, hospitalization, and decline that is its own life-threatening event.
The 12-Month Treatment Window
Evenity is limited to 12 monthly doses. The bone-forming effect peaks within the first few months and then gradually diminishes as the body adjusts, so extending treatment beyond a year doesn’t continue to add benefit at the same rate. This isn’t a lifelong medication.
What happens after those 12 months matters enormously. Without follow-up treatment, the bone density gains from Evenity will fade. The standard approach is to transition to a different class of osteoporosis drug (typically a bisphosphonate like alendronate or denosumab) to lock in the gains. Think of Evenity as the construction phase and the follow-up drug as the maintenance phase. Skipping the second step largely wastes the first.
Cost and Access
Evenity’s list price is about $2,629 per month, which totals roughly $31,500 for a full 12-month course. Because it requires administration by a healthcare professional, it falls under Medicare Part B rather than Part D, which changes how coverage works. Most insurance plans and Medicare require prior authorization, and your doctor will typically need to document that you meet the high-risk criteria.
Out-of-pocket costs vary widely depending on your coverage. Under Medicare Part B, you’re generally responsible for 20% of the approved amount after meeting your deductible, though supplemental insurance can reduce that further. The manufacturer also offers patient assistance programs for people who qualify based on income.
Weighing the Decision
The clearest cases are at the extremes. If you’ve had a heart attack or stroke, Evenity is off the table. If you have severe osteoporosis with previous fractures, no cardiovascular history, and other treatments haven’t worked, the fracture reduction benefits are substantial and the cardiovascular risk is relatively low. Most people fall somewhere in between, which is where the conversation gets nuanced.
A few questions worth discussing with your doctor: What is your 10-year fracture probability? Do you have any cardiovascular risk factors, and how well controlled are they? Have you tried other osteoporosis treatments, and if so, why did they fall short? The answers to those questions, taken together, determine whether the risk-benefit ratio tips in your favor. For the right patient, Evenity offers a level of fracture protection that no other drug currently matches.